Active Ingredient(s): Decitabine + Cedazuridine
FDA Approved: * July 7, 2020
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Inqovi Overview

Decitabine/cedazuridine, sold under the brand name Inqovi, is a fixed-dose combination medication for the treatment of adults with myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML).[5][6][7] It is a combination of decitabine, a nucleoside metabolic inhibitor, and cedazuridine, a cytidine deaminase inhibitor.[5][6][7] The most common side effects of decitabine/cedazuridine i...

Read more Inqovi Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Inqovi Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Decitabine + Cedazuridine
  • Tablet: 100mg + 35mg, 35mg + 100mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Inqovi: (1 result)

Sorted by National Drug Code
  • 64842-0727 Inqovi Oral Tablet, Film Coated by Taiho Pharmaceutical Co., Ltd.

Drugs with one or more similar ingredients: (3 results)